Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
A legfontosabb adatok
- Ki végzi
- Jian Zhu
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1. fázis
- Résztvevők
- 6 fő, tervezett
- Kezdés
- 2026. máj. 11.
- Várható befejezés
- 2028. máj. 11.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Universal STAR-T Cell
- A regiszteradat frissítve
- 2026. május 20.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a connective tissue disease who also have immune thrombocytopenia (low platelets caused by the immune system). This low-platelet problem has come back or did not respond to treatment. They will receive universal STAR-T cells.
- Életkor
- 18 to 65 years
- Nem
- All sexes
- A betegség stádiuma
- A confirmed connective tissue disease, such as SLE, primary Sjögren's syndrome, antiphospholipid syndrome or undifferentiated connective tissue disease. Also immune thrombocytopenia linked to it, with platelet count < 30 × 10⁹/L, or < 50 × 10⁹/L with a tendency to bleed. A bone marrow test must show signs of ITP.
- Korábbi kezelés
- People must not have reached partial remission after at least one of these, given for ≥ 3 months: glucocorticoid pulse therapy, or high-dose glucocorticoids with one or more immunosuppressants (including biologics). People whose response faded while lowering glucocorticoids can also join. No immunosuppressants that act on the disease within five half-lives before joining. No biological agents within four weeks before joining.
- Biomarker vagy leletérték
- Neutrophils ≥1×10^9/L, hemoglobin ≥60 g/L, ALT/AST ≤3×ULN, TBIL ≤1.5×ULN, CrCl≥30mL/min, INR/PT ≤1.5×ULN. Women who can have children need a negative serum HCG test within 7 days before joining.
A részvétel fő kizáró okai
- Uncontrolled infections, or a positive test for HIV, syphilis, active hepatitis B or hepatitis C
- Cancer within the past five years
- End-stage kidney failure or a heart that cannot cope with the treatment
- Severe drug allergies, or a congenital lack of immunoglobulins (antibodies)
- Pregnant or breastfeeding women, or women planning a pregnancy
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Age ranges from 18 to 65 years old (including threshold), regardless of gender
- Confirmed diagnosis of a connective tissue disease (CTD) according to the latest international classification criteria, including but not limited to Systemic Lupus Erythematosus (SLE), Primary Sjögren's Syndrome (pSS), Antiphospholipid Syndrome (APS), and Undifferentiated Connective Tissue Disease (UCTD)
- Confirmed diagnosis of CTD-associated immune thrombocytopenia meeting one of the following:; Platelet count < 30 × 10⁹/L; Platelet count < 50 × 10⁹/L accompanied by bleeding tendency
- Bone marrow morphology consistent with the characteristics of immune thrombocytopenia (ITP)
- Prior Treatment History: Failure to achieve partial remission (PR) after receiving at least one of the following regimens continuously for ≥ 3 months, or inability to maintain efficacy during glucocorticoid tapering:; At least one course of glucocorticoid pulse therapy; Or high-dose glucocorticoids combined with one or more immunosuppressants (including biologics)
- Essential Organ Function Criteria:
- Bone marrow: Neutrophils ≥1×10\^9/L (within 2 weeks, excluding granulocyte colony-stimulating factor use); Hemoglobin ≥60 g/L
- Liver: ALT/AST ≤3×ULN (disease-related elevations permitted). TBIL; ≤1.5×ULN (disease-related elevations permitted)
- Renal: CrCl≥30mL/min (Cockcroft-Gault formula, excluding acute declines)
- Coagulation: INR/PT ≤1.5×ULN
- Cardiovascular: Hemodynamic stability. 7. Fertile females or males with partners of childbearing age must use medically approved contraception or abstain during and ≥12 months post- treatment. Negative serum HCG test (within 7 days pre-enrollment) for fertile females; non-lactating
- Voluntary participation with signed informed consent and compliance
Ki nem vehet részt
- Subjects who meet any of the following exclusion criteria will not be admitted to the study:; Individuals with a severe history of drug allergies or those with an allergic constitution; Individuals with existing or suspected uncontrolled or treatable fungal, bacterial, viral, or other infections; Subjects with central nervous system diseases (excluding those with a history of epilepsy, psychiatric disorders, organic brain disease syndromes, cerebrovascular accidents, encephalitis, or central nervous system vasculitis resulting from the underlying disease); Subjects whose cardiac function cannot tolerate the study interventions; Subjects with congenital immunoglobulin deficiencies; Subjects with a history of malignant tumors within the past five years; Subjects with end-stage renal failure; Subjects who are positive for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titers exceeding the upper limit of detection; subjects who are positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; subjects who are positive for human immunodeficiency virus (HIV) antibody; and subjects who are positive for syphilis testing; Subjects with psychiatric disorders or severe cognitive dysfunction; Subjects who have participated in other clinical trials within the past three months prior to enrollment; Subjects who have received immunosuppressive agents with therapeutic effects on the disease within five half-lives prior to enrollment or biological agents within four weeks prior to enrollment; Pregnant women or women planning to become pregnant; Subjects whom the investigator believes have other reasons that preclude their inclusion in this study
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.
A teljes eredeti leírásKevesebb
This study evaluates the safety and efficacy of universal STAR-T cells in patients with R/R CTD-associated Immune Thrombocytopenia (CTD-ITP). Approximately 9 patients aged 18-65 will receive infusion of universal STAR-T cells at the starting dose of 3E6 STAR+T cells/kg. The main purpose of exploratory clinical research is to explore the efficacy and safety of universal STAR-T cell and the lymphodepletion regimen. The primary endpoint is observations of types, severity, and frequency of adverse events (AEs) and efficacy assessment. This single-arm, open-label trial will enroll patients across Chinese People's Liberation Army (PLA) General Hospital.
A vizsgálat csoportja
- Universal STAR-T CellA vizsgált kezelés
Subjects will receive infusion of Universal STAR-T Cells at the starting dose of 3E6 STAR+T cells/kg.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Exploratory Clinical Study of Universal STAR-T Cell Injection in Subjects With Relapsed/Refractory Autoimmune Diseases
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07599280: ki vehet részt
- A regiszteradat frissítve
- 2026. május 20.